RxDoctor Payments Data

Alan Geringer, MD

Urology · Baltimore, MDNPI 1114981065

Payments from drug & device makers

$1,604in general payments, 2019–2025

Across 85 payments — averaging $18.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$271
  • Johnson & Johnson$199
  • Pfizer$149
  • Indivior Inc.$147
  • Orexo US, Inc.$134
  • Gilead$106
  • plus $598 from 18 others
$125in research payments, 2019–2025

Across 1 payment — averaging $125.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Indivior Inc.$125

What the payments were for

  • Food & beverage$1,36985%
  • Education$23515%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,604 in reported general payments places this provider in the 35th percentile of 274 urology providers in Maryland.

See all urology providers in Maryland

Medicare billing

Part B allowed, 2024
$93,462
Medicare patients
270
Services billed
7,346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SublocadeBuprenorphine21$44,007
MyrbetriqMirabegron49$35,966
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl144$18,583
GemtesaVibegron32$16,065
SuboxoneBuprenorphine Hcl/Naloxone Hcl20$14,078
Tamsulosin Hcl253$5,341
Finasteride93$1,601
Solifenacin Succinate31$1,531
Silodosin12$1,502
Oxybutynin Chloride29$775
Testosterone14$365
Alfuzosin Hcl ErAlfuzosin Hcl11$177
Ciprofloxacin Hcl27$80

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Indivior Inc.Sublocade, Suboxone$147$58,08441 claims
Astellas Pharma US IncMyrbetriq$271$35,96649 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 274 urology providers in Maryland.

Other urology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →